Cargando…
SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done?
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel virus responsible for the current coronavirus disease 2019 (COVID-19) pandemic, has infected over 3.5 million people all over the world since the first case was reported from Wuhan, China 5 months ago. As more epidemiological data...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325192/ https://www.ncbi.nlm.nih.gov/pubmed/32612666 http://dx.doi.org/10.1186/s12979-020-00192-y |
_version_ | 1783552104538832896 |
---|---|
author | Mazucanti, Caio Henrique Egan, Josephine Mary |
author_facet | Mazucanti, Caio Henrique Egan, Josephine Mary |
author_sort | Mazucanti, Caio Henrique |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel virus responsible for the current coronavirus disease 2019 (COVID-19) pandemic, has infected over 3.5 million people all over the world since the first case was reported from Wuhan, China 5 months ago. As more epidemiological data regarding COVID-19 patients is acquired, factors that increase the severity of the infection are being identified and reported. One of the most consistent co-morbidities associated with worse outcome in COVID-19 patients is diabetes, along with age and cardiovascular disease. Studies on the association of diabetes with other acute respiratory infections, namely SARS, MERS, and Influenza, outline what seems to be an underlying factor in diabetic patients that makes them more susceptible to complications. In this review we summarize what we think may be the factors driving this pattern between diabetes, aging and poor outcomes in respiratory infections. We also review therapeutic considerations and strategies for treatment of COVID-19 in diabetic patients, and how the additional challenge of this co-morbidity requires attention to glucose homeostasis so as to achieve the best outcomes possible for patients. |
format | Online Article Text |
id | pubmed-7325192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73251922020-06-30 SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? Mazucanti, Caio Henrique Egan, Josephine Mary Immun Ageing Review Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel virus responsible for the current coronavirus disease 2019 (COVID-19) pandemic, has infected over 3.5 million people all over the world since the first case was reported from Wuhan, China 5 months ago. As more epidemiological data regarding COVID-19 patients is acquired, factors that increase the severity of the infection are being identified and reported. One of the most consistent co-morbidities associated with worse outcome in COVID-19 patients is diabetes, along with age and cardiovascular disease. Studies on the association of diabetes with other acute respiratory infections, namely SARS, MERS, and Influenza, outline what seems to be an underlying factor in diabetic patients that makes them more susceptible to complications. In this review we summarize what we think may be the factors driving this pattern between diabetes, aging and poor outcomes in respiratory infections. We also review therapeutic considerations and strategies for treatment of COVID-19 in diabetic patients, and how the additional challenge of this co-morbidity requires attention to glucose homeostasis so as to achieve the best outcomes possible for patients. BioMed Central 2020-06-30 /pmc/articles/PMC7325192/ /pubmed/32612666 http://dx.doi.org/10.1186/s12979-020-00192-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Mazucanti, Caio Henrique Egan, Josephine Mary SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? |
title | SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? |
title_full | SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? |
title_fullStr | SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? |
title_full_unstemmed | SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? |
title_short | SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? |
title_sort | sars-cov-2 disease severity and diabetes: why the connection and what is to be done? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325192/ https://www.ncbi.nlm.nih.gov/pubmed/32612666 http://dx.doi.org/10.1186/s12979-020-00192-y |
work_keys_str_mv | AT mazucanticaiohenrique sarscov2diseaseseverityanddiabeteswhytheconnectionandwhatistobedone AT eganjosephinemary sarscov2diseaseseverityanddiabeteswhytheconnectionandwhatistobedone |